MedTrace Logo

Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain

NCT02985216 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 371

Last updated 2019-01-16

No results posted yet for this study

Summary

A Randomized, Double-blind, Active-Controlled, Multi-center, Phase 3 Trial to Compare the Safety and Efficacy between YHD1119 and Pregabalin in Patients with Peripheral Neuropathic Pain

Conditions

  • Peripheral Neuropathic Pain

Interventions

DRUG

YHD1119

YHD1119 150mg, PO YHD1119 300mg, PO YHD1119 600mg, PO

DRUG

Lyrica

Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Yong Chul KIM, M.D.,Ph.D. · Seoul National University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-07
Primary Completion
2018-04-27
Completion
2018-05-02

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02985216 on ClinicalTrials.gov